What Skin Analytics does

Skin Analytics is a UK-based medical device company that develops and commercializes AI-powered dermatology software for autonomous skin cancer assessment. Founded in 2012, the company's flagship product is DERM (Deep Ensemble for the Recognition of Malignancy), a Class III CE-marked and UKCA Class IIa-certified AI as a Medical Device that uses custom deep learning ensembles to analyze images of skin lesions and triage patients into the appropriate care pathway. DERM identifies melanoma, squamous cell carcinoma, basal cell carcinoma, Bowen's disease, actinic keratosis, and atypical nevi with validated sensitivity thresholds of 95%+ for melanoma and SCC, and is deployed across more than 25 NHS partner sites in the UK, with over 230,000 patients assessed and 20,000+ cancers detected over six years of clinical use. In 2026 the company launched DERM Zero, a smartphone-compatible version of the same Class III regulated AI, extending deployment beyond hospitals to primary care, pharmacies, and community settings.

The company's business model centers on annual subscription fees (Annual Product Fees) paid by NHS trusts and healthcare providers for access to the DERM platform, supplemented by per-case fees of £20 for clinician reviews and custom software development at £850 per person day. Secondary revenue streams include Bupa-branded remote skin assessment services (where Skin Analytics invoices the insurer directly) and direct-to-consumer Mole Check and General Dermatology services in the UK. European expansion is being executed via channel partnerships with Affidea (pan-European, starting Romania and Lithuania) and Human Bytes (Nordic), with a stated objective of US market entry supported by the £15M Series B funding round closed in April 2025 led by Intrepid Growth Partners.

Skin Analytics is headquartered in London with a registered office in Cambridge, operates with 51-100 employees, and is led by founder and CEO Neil Daly alongside a clinical and AI leadership team including Dr Jack Greenhalgh (AI Director) and Dr Dilraj Kalsi (Clinical AI Lead). The company has accumulated an unusually deep stack of certifications and endorsements for a company of its size, including ISO 13485:2016, ISO 27001, NHS DSP Toolkit, Cyber Essentials, DCB 0129, DTAC, CQC registration, the NHSX Award (2021), CogX Best Innovation in Computer Vision (2019), G-Cloud 14 Framework placement (2024), and a NICE Early Value Assessment recommendation (2025) for use within NHS Trusts.

Name

Skin Analytics

Legal name

Skin Analytics Limited

Website

https://skin-analytics.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

51–100 employees

Short description

Skin Analytics is a UK-based medical device company that develops DERM, a Class III CE-marked AI platform using deep learning ensembles to autonomously screen skin lesions for cancer. The company sells annual subscriptions and per-case fees to NHS trusts, private insurers like Bupa, and European channel partners, and has assessed 230,000+ patients across 25+ NHS sites.

Ownership category

akta.pro rank

Product category

AI Dermatology Medical Devices

NAICS

Medical and Diagnostic Laboratories (62151)

SIC

Surgical & Medical Instruments & Apparatus (3841), Services-Health Services (8000)

akta.pro primary industry

Medical Imaging AI (HDAAAEAH)

akta.pro secondary industry

Dermatology Telemedicine Platforms (HLALAGAA)

Keywords

• Dermatology AI
• Skin cancer detection
• Medical imaging AI
• Teledermatology platform
• AI medical device

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. NHS and Healthcare Provider Contracts: Annual Product Fee paid by NHS trusts and healthcare providers for access to DERM platform and services, with additional per-case fees for clinician reviews (£20 per case). Custom software development available at £850 per person day.
2. Private Healthcare / Insurance: Bupa customers receive remote skin assessment services with Skin Analytics invoicing Bupa directly for assessments. Patients may receive invoices for any contribution towards costs not covered by their insurance policy.
3. European Licensing: Working with European partners to make DERM Zero available from June 2026, enabling clinical-grade skin cancer checks across EU primary care, pharmacies, and community settings.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels6 records

Core offering

Skin Analytics develops and sells DERM (Deep Ensemble for the Recognition of Malignancy), a Class III CE marked AI as a Medical Device that autonomously analyzes images of skin lesions to triage patients and detect melanoma, squamous cell carcinoma, basal cell carcinoma, and other skin cancers. The platform combines proprietary deep learning ensembles with a custom teledermatology system to integrate into NHS dermatology pathways. DERM Zero extends this Class III regulated AI to standard smartphones, enabling clinical-grade skin cancer assessment in primary care, pharmacies, and community settings without specialist equipment or hospital appointments.

Product overview

Skin Analytics offers a portfolio of AI-powered dermatology products centered on its Class III CE-marked DERM (Deep Ensemble for the Recognition of Malignancy) platform. DERM provides autonomous skin cancer detection using deep learning algorithms to analyze skin lesion images with 95%+ sensitivity for melanoma and squamous cell carcinoma. The product suite includes DERM (hospital/clinic-based with dermoscopic hardware), DERM Zero (smartphone-based autonomous assessment), and NHS pathway integrations combining AI triage with teledermatology review. Additional services include mole/lesion assessment for patients and general dermatology consultation services, with Bupa offering a branded remote skin assessment powered by Skin Analytics technology.

Differentiator

Problem solved

Functional benefit

Brands

• DERM: Deep Ensemble for the Recognition of Malignancy - Class III CE marked AI as a Medical Device for autonomous skin cancer detection. Powers both clinical pathway deployment and DERM Zero smartphone application.
• DERM Zero

Products and services

• DERM (Deep Ensemble for the Recognition of Malignancy) Class III CE-marked and UKCA Class IIa certified AI as a Medical Device (AIaMD) for autonomous skin cancer detection. DERM uses deep ensemble methods combining multiple neural network models to analyze dermoscopic images of skin lesions and triage patients for melanoma, squamous cell carcinoma, basal cell carcinoma, Bowen's disease, actinic keratosis, and atypical nevi with minimum sensitivity thresholds of 95% for melanoma and SCC. Built around a custom teledermatology platform for end-to-end skin cancer pathway management in NHS secondary and primary care.
• DERM Zero World's first Class III CE-marked medical device technology approved to autonomously assess skin cancer from a standard smartphone. DERM Zero enables clinical-grade skin cancer checks in primary care, pharmacies, or community settings without requiring a dermoscope or hospital appointment, processing images captured from standard smartphone cameras for autonomous skin cancer assessment using the same Class III regulated AI as DERM.
• Mole and Lesion Assessment Service Patient-facing direct-to-consumer service for assessing skin lesions using DERM technology, offering faster assessment and results within 24 hours compared to traditional face-to-face dermatology appointments. Available directly to UK patients through the Skin Analytics services website.
• General Dermatology Service Non-urgent general dermatology assessment service for skin concerns using the Skin Analytics platform with dermatologist review of uploaded images. Available directly to UK patients through the company's services website as a consumer offering.
• Bupa Remote Skin Assessment Partnership service with Bupa providing Bupa customers with access to a remote skin assessment using Skin Analytics technology. Customers receive a kit with a smartphone and dermoscopic lens, upload photos of moles via app alongside their medical history, and receive dermatologist assessment within 24 hours. Skin Analytics invoices Bupa directly for the assessment service.

Quantifiable outcome

• 99.5% accuracy in ruling out melanoma and skin cancer
• +5 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Human BytescoreChannel Partner/ Reseller/ Distributor · 4 November 2025Strategic partnership to bring DERM, the world's only autonomous AI for assessment and triage of suspected skin cancer, to the Nordic countries.
• AffideacoreStrategic or Co-development Partner · 18 August 2025Pan-European provider of community-based polyclinics and advanced diagnostics has partnered with Skin Analytics to implement AI-based skin cancer detection across several European countries, starting with Romania and Lithuania. Aims to improve early diagnosis and patient access to skin cancer care with plans to expand further in Europe.
• BupacoreChannel Partner/ Reseller/ DistributorBupa has engaged Skin Analytics to provide its customers with access to a new remote skin assessment service. Customers receive a kit with smartphone and dermoscopic lens, upload photos via app, and receive dermatologist assessment within 24 hours. Skin Analytics invoices Bupa directly for this service.
• DigitalHealth.LondonminorStrategic or Co-development PartnerNHS accelerator program that supported Skin Analytics since 2016 as part of their journey to bring AI skin cancer detection technology to the NHS.
• NHS National Innovation AcceleratorminorStrategic or Co-development PartnerNHS program supporting Skin Analytics since 2016 to accelerate adoption of innovative AI technology in the NHS.
• Healthdirect AustraliaminorStrategic or Co-development PartnerHealthdirect Australia is testing an integration with ChatGPT to create a health assistant, collaborating with Infermedica, Skin Analytics, AWS, and DEPT on the project.
• NHS Trusts (Various)coreChannel Partner/ Reseller/ Distributor25+ NHS partners using DERM across NHS sites including Chelsea and Westminster Hospital, Ashford & St. Peter's Hospitals, West Suffolk NHS Foundation Trust, Manchester University NHS Foundation Trust, and others. Jersey GP Surgery became first in Channel Islands to use DERM.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• First Derm: Teledermatology platform connecting users to dermatologists for asynchronous skin lesion assessment. Comparable as a remote skin assessment service provider, though relies on human clinician review rather than autonomous AI.
• HeartFlow: US company offering AI-driven non-invasive cardiac diagnostic analysis with multiple regulatory clearances and established reimbursement. Comparable as a regulated AI medical device company with deep clinical evidence, NHS-relevant footprint, and similar enterprise sales motion.
• VisualDx: US clinical decision support platform used by dermatologists and primary care for image-based differential diagnosis. Comparable as an AI/imaging dermatology decision support tool used in clinical workflows, though primarily clinician-facing reference rather than autonomous triage.

Direct peers

• Canfield Scientific: US-based leader in dermatology imaging systems (VECTRA, IntelliStudio, DermaGraphix) with AI features for skin lesion analysis. Comparable provider of imaging and AI tools used by dermatology clinics and research institutions.
• SkinVision: Amsterdam-based AI dermatology company offering a CE-marked smartphone app for skin cancer risk assessment. Direct competitor in autonomous dermatology AI targeting both consumer and B2B channels across Europe and Australia.
• DermaSensor: US-based developer of an FDA-cleared handheld AI device for primary care skin cancer detection. Direct competitor in autonomous dermatology AI with FDA clearance, pursuing the same primary-care workflow Skin Analytics targets with DERM Zero.
• FotoFinder Systems: German manufacturer of dermoscopy hardware and AI-based skin imaging software used by dermatologists worldwide. Comparable as a provider of AI-assisted dermatology imaging used in clinical workflows and mole monitoring.
• MetaOptima (MoleScope / DermEngine): Canadian company offering DermEngine (teledermatology/AI imaging platform) and MoleScope (smartphone dermoscopy attachment). Comparable as a combined AI imaging plus smartphone dermoscopy workflow targeting dermatologists and primary care.
• IDx / Digital Diagnostics: Pioneer of fully autonomous AI diagnostics (IDx-DR, the first FDA-authorised autonomous AI diagnostic). Comparable as a regulated autonomous AI medical device company targeting primary care workflow, providing a regulatory and commercial precedent for Skin Analytics.

Broad incumbents

• Siemens Healthineers (AI-Rad Companion): Global medical imaging incumbent offering a portfolio of AI-assisted radiology and imaging applications, including dermatology-adjacent imaging AI. Comparable as a broad incumbent that could bundle AI dermatology tools into enterprise imaging contracts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/skinanalytics
• LinkedInlinkedin.com/company/skin-analytics
• Facebookfacebook.com/SkinAnalytics

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds18 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Skin Analytics